These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34740610)

  • 21. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
    Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Front Immunol; 2021; 12():622001. PubMed ID: 33737929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
    Blumenthal RD; Osorio L; Hayes MK; Horak ID; Hansen HJ; Goldenberg DM
    Cancer Immunol Immunother; 2005 Apr; 54(4):315-27. PubMed ID: 15592930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.
    Porter LH; Harrison SG; Risbridger GP; Lister N; Taylor RA
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106571. PubMed ID: 38909866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.
    Jancewicz I; Śmiech M; Winiarska M; Zagozdzon R; Wisniewski P
    Cancer Immunol Immunother; 2024 Jan; 73(2):30. PubMed ID: 38279989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
    Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
    Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
    Ajkunic A; Sayar E; Roudier MP; Patel RA; Coleman IM; De Sarkar N; Hanratty B; Adil M; Zhao J; Zaidi S; True LD; Sperger JM; Cheng HH; Yu EY; Montgomery RB; Hawley JE; Ha G; Lee JK; Harmon SA; Corey E; Lang JM; Sawyers CL; Morrissey C; Schweizer MT; Gulati R; Nelson PS; Haffner MC
    Res Sq; 2023 Dec; ():. PubMed ID: 38196594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
    Hillerdal V; Ramachandran M; Leja J; Essand M
    BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
    Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
    Ajkunic A; Sayar E; Roudier MP; Patel RA; Coleman IM; De Sarkar N; Hanratty B; Adil M; Zhao J; Zaidi S; True LD; Sperger JM; Cheng HH; Yu EY; Montgomery RB; Hawley JE; Ha G; Persse T; Galipeau P; Lee JK; Harmon SA; Corey E; Lang JM; Sawyers CL; Morrissey C; Schweizer MT; Gulati R; Nelson PS; Haffner MC
    NPJ Precis Oncol; 2024 May; 8(1):104. PubMed ID: 38760413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
    Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
    Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
    Wu L; Liu F; Yin L; Wang F; Shi H; Zhao Q; Yang F; Chen D; Dong X; Gu Y; Xing N
    Cancer Commun (Lond); 2022 Aug; 42(8):768-783. PubMed ID: 35706368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.
    Zheng C; Feng J; Lu D; Wang P; Xing S; Coll JL; Yang D; Yan X
    PLoS One; 2011; 6(6):e21146. PubMed ID: 21731662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
    Zaidi S; Park J; Chan JM; Roudier MP; Zhao JL; Gopalan A; Wadosky KM; Patel RA; Sayar E; Karthaus WR; Kates DH; Chaudhary O; Xu T; Masilionis I; Mazutis L; Chaligné R; Obradovic A; Linkov I; Barlas A; Jungbluth AA; Rekhtman N; Silber J; Manova-Todorova K; Watson PA; True LD; Morrissey C; Scher HI; Rathkopf DE; Morris MJ; Goodrich DW; Choi J; Nelson PS; Haffner MC; Sawyers CL
    Proc Natl Acad Sci U S A; 2024 Jul; 121(28):e2322203121. PubMed ID: 38968122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
    Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
    J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity.
    Zhu XY; Li QX; Kong Y; Huang KK; Wang G; Wang YJ; Lu J; Hua GQ; Wu YL; Ying TL
    Acta Pharmacol Sin; 2024 Mar; 45(3):609-618. PubMed ID: 38030799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
    Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
    Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis.
    Gu S; Zaidi S; Hassan MI; Mohammad T; Malta TM; Noushmehr H; Nguyen B; Crandall KA; Srivastav J; Obias V; Lin P; Nguyen BN; Yao M; Yao R; King CH; Mazumder R; Mishra B; Rao S; Mishra L
    Gastroenterology; 2020 Jan; 158(1):238-252. PubMed ID: 31585122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current Trend of CAR-T Cell Therapy for Metastatic Castration-Resistant Prostate Cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1038-1042. PubMed ID: 38035830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.